# Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

> **NCT02839343** · PHASE2 · UNKNOWN · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 126 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Borderline Resectable Adenocarcinoma of the Head of the Pancrease

## Interventions

- **RADIATION:** radiation therapy
- **PROCEDURE:** surgery
- **DRUG:** mFOLFIRINOX
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT02839343
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2020-11-30
- **Final completion:** —
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839343, "Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02839343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*